Does lupron provide a better outcome for first line treatment in Thesis

Does lupron provide a better outcome for first line treatment in advanced prostate cancer - Thesis Example Introduction In spite of all the dramatic advances in the understanding of disease processes, medical science and medical technologies, cancer remains a disease of special focus in present times, because of the challenges that it continues to pose as a life threatening disease. Most of the cancer diseases tend to be chronic, with a strong possibility of causing the death of the individual, yet take years to develop, before presenting any signs and symptoms of the disease. There is limited clarity in how cancer diseases develop and the exact etiology of most cancers is yet to be clearly defined. Treatment of many cancers involves employing repeated interventions and multiple approaches at the different stages of the disease. The treatment strategy in many of the cancer diseases is more of hope at curing the patients and with the more definite aim of managing the disease, so as to extend the period of survival, with better quality of life in terms of comfort alertness, and function. In the United States of America (U.S.A) the disease of cancer continues to remain a major concern in society, as many of the modern diseases show a declining trend, bit in the case of the cancer diseases more people are developing the disease over the few decades (Grenwald, 2002). Prostate cancer is a cancer that affects the male gender only. Widespread use of prostate-specific antigen (PSA) screening is used in U.S.A. to detect prostate cancer, while it is clinically localized, so that the many forms of interventions available for the early stage of prostate cancer may be used in an attempt to cure the patient of the disease. Yet, many patients still present themselves in hospitals demonstrating evidence of progressive, metastatic, or recurrent prostate cancer. Limited effective treatment strategies are possible in advanced prostate cancer, and in many of the cases, the disease progresses to the palliative care stage. In 2008, 28,660 men died in the U.S.A from prostate cancer, making it the most common malignant disease in men. This statistic points to the need for identifying the treatment strategies that provide the best outcomes for advanced prostate cancer in men, so as to improve the outcome for these patients (Phillips & Petrylak, 2010). 2. Literature Review 2.1. Development of Prostrate Cancer Every cancer has been found to be associated or suspected of association with risk factors. In the case of prostate cancer, evidence from studies have shown that the environmental exposures and dietary nutrients, family history, advancement in age and hormonal factors in conjunction act to alter the genetic architecture in the individual, supporting the proliferation of prostate cancer cells. The use of epidemiological data emphasizes the possibility of environmental factors in the development of prostate cancer. For example, Asians as a racial group are less prone to prostate cancer, for which their poor hygiene and diet are believed to be the cause. This can be s een from Asian migrants in the